Drug Name: Jaypirca

Indications: To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor

Active Ingredient: Pirtobrutinib

Company: Eli Lilly and Company

Approval Date: 1/27/2023                                                                                

More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216059Orig1s000Corrected_lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *